Advertisement
Screener

Summit Therapeutics Inc. (SMMT) Analyst Insights

RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$16.34(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$16.34High(m)Average(m)Low(m)2025-11-062026-11-06
DateStockAnalystFirmPrice When RatedPrice TargetUpside / DownsideRatingPerformance
2025-12-17SMMT
Summit Therapeutics Inc.
Etzer Darout, PhD, MBABarclays$17.38$18.00+3.57%Equal Weight
2025-10-21SMMT
Summit Therapeutics Inc.
Etzer Darout, PhD, MBABarclays$20.04$16.00-20.16%Underweight
2025-09-16SMMT
Summit Therapeutics Inc.
Etzer Darout, PhD, MBABarclays$18.12$13.00-28.26%Underweight

Similar stocks

Stock NameCountryMarket CapPE Ratio
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52